Alex Philippidis
Senior Business Editor at Genetic Engineering & Biotechnology News
Senior Business Editor, Genetic Engineering & Biotechnology News, GEN Edge, and Mary Ann Liebert Inc., New Rochelle, NY. https://t.co/b3rRmjLrzs
Articles
-
1 day ago |
genengnews.com | Alex Philippidis |Fay Y. Lin |Uduak Grace Thomas |Corinna Singleman
A gene therapy clinical trial for Danon disease run by Rocket Pharmaceuticals has been suspended following the death of a patient. MIT and Recursion have released Boltz-2, an open-source tool that predicts molecular binding affinity at newfound speed and accuracy, aiming to democratize commercial drug discovery. Intellia Therapeutics saw its stock nosedive late last week after a patient in its Phase III trial of the CRISPR-based therapy experienced non-lethal liver toxicity.
-
1 day ago |
genengnews.com | Kevin Davies |Alex Philippidis
Leaders from the world of cell and gene therapy, including molecular geneticists, immunotherapists, physicians, nonprofit directors, and patient advocates, shared their personal stories and policy recommendations with leaders of the FDA in an extraordinary roundtable. The roundtable was conducted in front of the FDA’s recently appointed top officials—director Martin A. Makary, MD, and Vinayak (Vinay) Kashyap Prasad, MD, director of the Center for Biologics Evaluation and Research.
-
3 days ago |
genengnews.com | Alex Philippidis
Bristol Myers Squibb (BMS) has agreed to co-develop and co-commercialize BioNTech’s cancer-fighting bispecific antibody candidate BNT327 across numerous solid tumor types through a collaboration that could generate up to $11.1 billion for the German next-generation immunotherapy developer, the companies said.
-
4 days ago |
genengnews.com | Alex Philippidis
Home Topics Artificial Intelligence Insilico Eyes Q4 Start for Late-Stage Trials of IPF Candidate Artificial intelligence (AI) drug developer Insilico Medicine says it is planning late-stage trials for its lead clinical candidate rentosertib following publication today of positive mid-stage safety and efficacy data for the idiopathic pulmonary fibrosis (IPF) candidate.
-
5 days ago |
genengnews.com | Alex Philippidis
Home Topics Drug Discovery Sanofi to Acquire Blueprint Medicines for Up to $9.5B Sanofi has agreed to acquire Blueprint Medicines for up to approximately $9.5 billion, in a deal designed to expand the buyer’s rare immunological disease portfolio with an FDA-approved treatment, as well as an early-stage pipeline of immunological drug candidates.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 5K
- Tweets
- 13K
- DMs Open
- No
RT @GENbio: Top 10 Best-Selling Gene Therapies While five developers have raised $534M+ in financing so far this year, a CRO/CDMO shutdown…
SundayBest (Kontakion of Sunday of the Paralytic, 3d Tone): I am grievously paralyzed in a multitude of sins and wrongful deeds. As You raised up the paralytic of old, also raise up my soul by Your divine guidance, that I may cry out, "Glory to Your Power O Compassionate Christ." https://t.co/oidJMMjRre
7May: What two specialties did @bmsnews Board Chair and CEO Christopher Boerner PhD cite as areas of interest as he committed $BMY to spending $40B over five years to boost U.S. R&D, #manufacturing, & tech? My latest for @GENbio: https://t.co/vwRqgMdsLJ